Sanofi's Rilzabrutinib Gets EU Orphan Designation
Ticker: SNYNF · Form: 6-K · Filed: Aug 29, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-designation, orphan-drug, rare-disease, pharmaceuticals
TL;DR
EU grants Sanofi's rilzabrutinib orphan status for rare disease.
AI Summary
On August 14, 2025, Sanofi announced that its drug rilzabrutinib received Orphan Drug Designation from the European Union for the treatment of IgG4-related disease. This designation is granted to medicines intended for the diagnosis, prevention, or treatment of rare diseases or conditions that are life-threatening or chronically debilitating.
Why It Matters
This designation could accelerate the development and review of rilzabrutinib in the EU, potentially bringing a new treatment option to patients with a rare and serious condition.
Risk Assessment
Risk Level: low — This filing is an informational report (6-K) about a regulatory designation, not a financial transaction or operational update that would typically carry higher risk.
Key Players & Entities
- Sanofi (company) — Registrant and developer of rilzabrutinib
- rilzabrutinib (drug) — Drug that received orphan designation
- European Union (geography) — Granted the orphan drug designation
- August 14, 2025 (date) — Date of the press release
FAQ
What is the significance of Orphan Drug Designation in the EU?
Orphan Drug Designation in the EU is granted to medicines intended for the diagnosis, prevention, or treatment of rare diseases or conditions that are life-threatening or chronically debilitating. It can provide incentives such as market exclusivity and protocol assistance.
What condition does rilzabrutinib target with this designation?
Rilzabrutinib has received orphan designation for the treatment of IgG4-related disease.
When was this designation announced?
The press release announcing the designation was dated August 14, 2025.
What type of filing is this for Sanofi?
This is a Form 6-K report, which is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is Sanofi's primary business?
Sanofi is primarily involved in Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
Filing Stats: 181 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2025-08-29 10:36:03
Filing Documents
- d86864d6k.htm (6-K) — 8KB
- d86864dex991.htm (EX-99.1) — 17KB
- g86864g75o58.jpg (GRAPHIC) — 4KB
- g86864g90z17.jpg (GRAPHIC) — 6KB
- 0001193125-25-192215.txt ( ) — 39KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: August 29, 2025 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3